NantHealth and NantOmics to Present Data on Three-fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 4, 2018 | Press Releases

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...

NantHealth and NantOmics to Share Data on Next-generation Sequencing of Paired DNA and RNA Analysis of Rare Tumors at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 4, 2018 | Press Releases

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting  CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...

Nanthealth and Nantomics to Present Data on the Frequency of Non-expressed Variants Tested by Standard NGS Panel at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 4, 2018 | Press Releases

Results to be presented during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting  CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading...

NANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine

by Jen Hodson | Jun 3, 2018 | Press Releases

The FDA has authorized a phase 1 study for an investigational Neoepitope Yeast Vaccine, YE-NEO-001, in patients previously treated for cancer CHICAGO – June 3, 2018 — NANT, a technology and research company connecting breakthrough research in biology, healthcare and...

NantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

by Jen Hodson | Jun 2, 2018 | Press Releases

Genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer (TNBC) to a unique molecular signature.  The  results to be presented during the breast cancer session at ASCO 2018 Annual Meeting CHICAGO, IL – June...